Litcius/Paper detail

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Ghassan K. Abou‐Alfa, Teresa Macarulla, Milind Javle, Robin Kate Kelley, Sam Joseph Lubner, Jorge Adeva, James M. Cleary, Daniel V.T. Catenacci, Mitesh J. Borad, John Bridgewater, William Proctor Harris, Adrian Murphy, Do‐Youn Oh, Jonathan Whisenant, Maeve A. Lowery, Lipika Goyal, Rachna T. Shroff, Anthony B. El-Khoueiry, Bin Fan, Bin Wu, Christina X. Chamberlain, Liewen Jiang, Camelia Gliser, Shuchi S. Pandya, Juan W. Valle, Andrew X. Zhu

2020The Lancet Oncology1,077 citationsDOIOpen Access PDF

Topics & Concepts

Refractory (planetary science)MedicinePlaceboDouble blindIDH1OncologyChemotherapyInternal medicineMutantPathologyBiologyAlternative medicineBiochemistryAstrobiologyGeneCholangiocarcinoma and Gallbladder Cancer StudiesHepatocellular Carcinoma Treatment and PrognosisGastric Cancer Management and Outcomes